Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis

Significance Failure of the host immune system to control infection with Mycobacterium tuberculosis is a major determinant of tuberculosis (TB) disease. In this work, we examined the role of macrophage migration inhibitory factor (MIF), a cytokine that is encoded in a functionally polymorphic locus in humans, in TB. We found genetic low expressers of MIF to be enriched in a population of patients with HIV and disseminated TB. From our work in cellular and mouse models, we propose a key mechanism by which MIF regulates bacterial recognition as the first step in triggering inflammatory pathways to enable mycobacterial control. Macrophage migration inhibitory factor (MIF), an innate cytokine encoded in a functionally polymorphic genetic locus, contributes to detrimental inflammation but may be crucial for controlling infection. We explored the role of variant MIF alleles in tuberculosis. In a Ugandan cohort, genetic low expressers of MIF were 2.4-times more frequently identified among patients with Mycobacterium tuberculosis (TB) bacteremia than those without. We also found mycobacteria-stimulated transcription of MIF and serum MIF levels to be correlated with MIF genotype in human macrophages and in a separate cohort of US TB patients, respectively. To determine mechanisms for MIF’s protective role, we studied both aerosolized and i.v. models of mycobacterial infection and observed MIF-deficient mice to succumb more quickly with higher organism burden, increased lung pathology, and decreased innate cytokine production (TNF-α, IL-12, IL-10). MIF-deficient animals showed increased pulmonary neutrophil accumulation but preserved adaptive immune response. MIF-deficient macrophages demonstrated decreased cytokine and reactive oxygen production and impaired mycobacterial killing. Transcriptional investigation of MIF-deficient macrophages revealed reduced expression of the pattern recognition receptor dectin-1; restoration of dectin-1 expression recovered innate cytokine production and mycobacterial killing. Our data place MIF in a crucial upstream position in the innate immune response to mycobacteria and suggest that commonly occurring low expression MIF alleles confer an increased risk of TB disease in some populations.

[1]  M. Newport,et al.  Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population , 2013, BMC Medical Genetics.

[2]  S. Ehlers,et al.  Mincle is not essential for controlling Mycobacterium tuberculosis infection. , 2013, Immunobiology.

[3]  T. Calandra,et al.  Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis. , 2012, The Journal of infectious diseases.

[4]  Ming Chen,et al.  Association of tuberculosis and polymorphisms in the promoter region of macrophage migration inhibitory factor (MIF) in a Southwestern China Han population. , 2012, Cytokine.

[5]  S. Chow,et al.  Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Baeten,et al.  The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: A prospective intervention study* , 2012, Critical care medicine.

[7]  John P. Ray,et al.  Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections , 2012, Cell.

[8]  M. Bochud,et al.  A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  H. Urlaub,et al.  Syk Kinase-Coupled C-type Lectin Receptors Engage Protein Kinase C-δ to Elicit Card9 Adaptor-Mediated Innate Immunity , 2012, Immunity.

[10]  Ruth R. Montgomery,et al.  Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[11]  M. Pirmohamed,et al.  Early Deaths During Tuberculosis Treatment Are Associated With Depressed Innate Responses, Bacterial Infection, and Tuberculosis Progression , 2011, The Journal of infectious diseases.

[12]  A. O’Garra,et al.  The role of IL-10 in immune regulation during M. tuberculosis infection , 2011, Mucosal Immunology.

[13]  F. Vannberg,et al.  Human genetic susceptibility to intracellular pathogens , 2011, Immunological reviews.

[14]  G. Kaplan,et al.  Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice , 2011, PloS one.

[15]  A. Sher,et al.  The Syk/CARD9-coupled receptor Dectin-1 is not required for host resistance to Mycobacterium tuberculosis in mice , 2011, Microbes and infection.

[16]  J. Flynn,et al.  HIV-1/Mycobacterium tuberculosis Coinfection Immunology: How Does HIV-1 Exacerbate Tuberculosis? , 2011, Infection and Immunity.

[17]  Dongwan D. Kang,et al.  Profiling Early Lung Immune Responses in the Mouse Model of Tuberculosis , 2011, PloS one.

[18]  W. L. Jorgensen,et al.  Receptor agonists of macrophage migration inhibitory factor. , 2010, Bioorganic & medicinal chemistry letters.

[19]  Gordon D. Brown,et al.  Dectin-1: a role in antifungal defense and consequences of genetic polymorphisms in humans , 2010, Mammalian Genome.

[20]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[21]  J. Crump,et al.  Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[22]  H. Mollenkopf,et al.  The adaptor molecule CARD9 is essential for tuberculosis control , 2010, The Journal of experimental medicine.

[23]  Javier Martín,et al.  Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. , 2010, Journal of genetics and genomics = Yi chuan xue bao.

[24]  M. Möller,et al.  Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. , 2010, Tuberculosis.

[25]  E. de Wit,et al.  Past, present and future directions in human genetic susceptibility to tuberculosis. , 2010, FEMS immunology and medical microbiology.

[26]  M. Lasbury,et al.  Downregulation of PU.1 Leads to Decreased Expression of Dectin-1 in Alveolar Macrophages during Pneumocystis Pneumonia , 2010, Infection and Immunity.

[27]  N. Kenya-Mugisha,et al.  Severe Sepsis in Two Ugandan Hospitals: a Prospective Observational Study of Management and Outcomes in a Predominantly HIV-1 Infected Population , 2009, PloS one.

[28]  L. Leng,et al.  MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. , 2009, The Journal of infectious diseases.

[29]  L. Weissfeld,et al.  The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community‐acquired pneumonia , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  J. Bernhagen,et al.  The Golgi-Associated Protein p115 Mediates the Secretion of Macrophage Migration Inhibitory Factor1 , 2009, The Journal of Immunology.

[31]  N. Gow,et al.  Pattern recognition: recent insights from Dectin-1 , 2009, Current opinion in immunology.

[32]  L. Leng,et al.  Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  S. Akira,et al.  Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, ‐4 and ‐9 , 2008, European journal of immunology.

[34]  J. V. van Dissel,et al.  Heredity versus environment in tuberculosis in twins: the 1950s United Kingdom Prophit Survey Simonds and Comstock revisited. , 2007, American journal of respiratory and critical care medicine.

[35]  A. Sher,et al.  Dectin-1 Interaction with Mycobacterium tuberculosis Leads to Enhanced IL-12p40 Production by Splenic Dendritic Cells1 , 2007, The Journal of Immunology.

[36]  J. Anaya,et al.  Macrophage migration inhibitory factor gene influences the risk of developing tuberculosis in northwestern Colombian population. , 2007, Tissue antigens.

[37]  David L. Williams,et al.  Syk‐dependent ERK activation regulates IL‐2 and IL‐10 production by DC stimulated with zymosan , 2007, European journal of immunology.

[38]  F. Sweep,et al.  Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. , 2007, Clinical immunology.

[39]  T. van der Poll,et al.  Mice lacking SIGNR1 have stronger T helper 1 responses to Mycobacterium tuberculosis. , 2007, Microbes and infection.

[40]  M. Yadav,et al.  The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. , 2006, Blood.

[41]  Zeny Z. Feng,et al.  Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. , 2006, Arthritis and rheumatism.

[42]  T. Calandra,et al.  Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid‐induced expression of mitogen‐activated protein kinase phosphatase‐1 , 2005, European journal of immunology.

[43]  L. Leng,et al.  Role for macrophage migration inhibitory factor in asthma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Underhill,et al.  Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. , 2005, Blood.

[45]  Sung-Hwan Park,et al.  Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies , 2005, Nucleic acids research.

[46]  R. Bucala,et al.  Macrophage Migration Inhibitory Factor Reduces the Growth of Virulent Mycobacterium tuberculosis in Human Macrophages , 2005, Infection and Immunity.

[47]  S. Gordon,et al.  Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. , 2005, Immunity.

[48]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[49]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[50]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[51]  C. Sousa Faculty Opinions recommendation of Dectin-1 mediates the biological effects of beta-glucans. , 2003 .

[52]  S. Gordon,et al.  Dectin-1 Mediates the Biological Effects of β-Glucans , 2003, The Journal of experimental medicine.

[53]  P. Gregersen,et al.  Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. , 2003, Arthritis and rheumatism.

[54]  I. Orme,et al.  In Vivo IL-10 Production Reactivates Chronic Pulmonary Tuberculosis in C57BL/6 Mice1 , 2002, The Journal of Immunology.

[55]  S. Kaufmann,et al.  Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Chaisson,et al.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial , 2002, The Lancet.

[57]  S. Abe,et al.  Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. , 2002, Clinical immunology.

[58]  John David,et al.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  T. Calandra,et al.  MIF regulates innate immune responses through modulation of Toll-like receptor 4 , 2001, Nature.

[60]  Chris D. Clark,et al.  Spectrographic imaging: A bird's-eye view of the health of coral reefs , 2001, Nature.

[61]  A. Satoskar,et al.  Migration-Inhibitory Factor Gene-Deficient Mice Are Susceptible to Cutaneous Leishmania major Infection , 2001, Infection and Immunity.

[62]  Tina Peng,et al.  Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) , 1999, The Journal of Biological Chemistry.

[63]  A. Satoskar,et al.  Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.

[64]  H. Whittle,et al.  Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. , 1998, The New England journal of medicine.

[65]  G. Kaplan,et al.  Aerosol Infection of Mice with Mycobacteria Using a Nose-Only Exposure Device , 1997 .

[66]  R. Bucala,et al.  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.

[67]  R. Bucala,et al.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Bernhagen,et al.  An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction , 1996, The Journal of experimental medicine.

[69]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[70]  K. Tanaka,et al.  Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis , 1995, Infection and immunity.

[71]  J. Bernhagen,et al.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.

[72]  W. Stead,et al.  Racial differences in susceptibility to infection by Mycobacterium tuberculosis. , 1990, The New England journal of medicine.

[73]  S. Vermund,et al.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[74]  P. Barnes,et al.  Predictors of short-term prognosis in patients with pulmonary tuberculosis. , 1988, The Journal of infectious diseases.

[75]  J. David Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[76]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.

[77]  K. Alagarasu,et al.  Immunogenetics of HIV and HIV associated tuberculosis. , 2012, Tuberculosis.

[78]  D. Bratton Neutrophil Clearance: when the party’s over, cleanup begins , 2011 .

[79]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[80]  G. D. Brown,et al.  Immune recognition. A new receptor for beta-glucans. , 2001, Nature.

[81]  R. Atkins,et al.  Migration inhibitory factor expression in experimentally induced endotoxemia. , 1997, The American journal of pathology.